Finance

Lists
ALKEM:NSE
Alkem Laboratories Ltd
₹5 145,00
-1,48%
(-77,50) 1D
19 Nov., 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for ALKEM...
Open
₹5 220,00
High
₹5 233,50
Low
₹5 115,00
Mkt. cap
615,17 mjd.
Avg. vol.
154,41 k
Volume
243,63 k
Dividend
1,03%
Quarterly dividend
₹13,25
Ex-dividend date
07 Aug. 2026
P/E ratio
29,75
52-wk high
₹5 933,50
52-wk low
₹4 811,00
EPS
₹172,94
Shares outstanding
119,55 m.
No. of employees
19 k
Open
₹5 220,00
High
₹5 233,50
Low
₹5 115,00
Mkt. cap
615,17 mjd.
Avg. vol.
154,41 k
Volume
243,63 k
Dividend
1,03%
Quarterly dividend
₹13,25
Ex-dividend date
07 Aug. 2026
P/E ratio
29,75
52-wk high
₹5 933,50
52-wk low
₹4 811,00
EPS
₹172,94
Shares outstanding
119,55 m.
No. of employees
19 k
News stories
From web sources and news partners
Profile
Alkem Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Specialising in generics and speciality pharmaceuticals, Alkem manufactures and markets pharmaceutical generics, formulations and nutraceuticals across India and global markets. Wikipedia
About Alkem Laboratories Ltd
CEO-
Employees19,3 k
Founded1973
HeadquartersMumbai, Maharashtra, Indië
SectorHealth Care
IndustryPharmaceutical industry
Last report
12 Nov. 2026
Fiscal period
Q2 2027
₹54,52 / ₹56,40
-3,32%miss
Revenue / Est. (INR)
45,52 mjd. / 44,84 mjd.
+1,51%beat
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Des. 2025
Mrt. 2026
Jun. 2026
Sep. 2026
Revenue
37,37 mjd.
36,03 mjd.
37,40 mjd.
45,52 mjd.
Cost of goods sold
12,73 mjd.
14,33 mjd.
12,01 mjd.
14,95 mjd.
Cost of revenue
12,73 mjd.
14,33 mjd.
12,01 mjd.
14,95 mjd.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7,22 mjd.
17,12 mjd.
8,09 mjd.
8,97 mjd.
Operating expense
17,31 mjd.
17,80 mjd.
18,73 mjd.
21,69 mjd.
Total operating expenses
30,04 mjd.
32,13 mjd.
30,74 mjd.
36,64 mjd.
Operating income
7,33 mjd.
3,90 mjd.
6,66 mjd.
8,88 mjd.
Other non operating income
1,43 mjd.
-3,55 mjd.
1,53 mjd.
1,34 mjd.
EBT including unusual items
7,81 mjd.
4,22 mjd.
7,71 mjd.
9,99 mjd.
EBT excluding unusual items
8,33 mjd.
4,77 mjd.
7,71 mjd.
9,64 mjd.
Income tax expense
1,28 mjd.
1,71 mjd.
2,50 mjd.
3,32 mjd.
Effective tax rate
16,35%
40,53%
32,47%
33,22%
Other operating expenses
9,15 mjd.
-378,70 m.
9,64 mjd.
11,36 mjd.
Net income
6,36 mjd.
2,36 mjd.
5,20 mjd.
6,75 mjd.
Net profit margin
17,02%
6,56%
13,90%
14,84%
Earnings per share
56,88
26,50
43,49
54,52
Interest and investment income
-
3,92 mjd.
-
-
Interest expense
-421,00 m.
-336,50 m.
-466,20 m.
-576,70 m.
Net interest expenses
-421,00 m.
3,58 mjd.
-466,20 m.
-576,70 m.
Depreciation and amortization charges
950,10 m.
1,06 mjd.
1,00 mjd.
1,37 mjd.
EBITDA
8,11 mjd.
4,67 mjd.
7,43 mjd.
10,07 mjd.
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google-programme